Paulus Stoffels - Johnson Johnson Chairman
| JNJ Stock | MXN 3,168 3.63 0.11% |
Chairman
Dr. Paulus A. Stoffels is the Vice Chairman Executive Committee, Chief Scientific Officer of the Company. Dr. Stoffels joined the Company in 2002 with the acquisition of Tibotec Virco NV, where he was Chief Executive Officer of Virco NV and Chairman of Tibotec NV. In 2005, he was appointed Company Group Chairman, Global Virology. In 2006, he assumed the role of Company Group Chairman, Pharmaceuticals, with responsibility for worldwide research and development for the Central Nervous System and Internal Medicine Franchises since 2018.
| Age | 57 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Phone | 732 524 0400 |
| Web | https://www.jnj.com |
Johnson Johnson Management Efficiency
The company has return on total asset (ROA) of 0.0881 % which means that it generated a profit of $0.0881 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2414 %, meaning that it generated $0.2414 on every $100 dollars invested by stockholders. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | CHAIRMAN Age | ||
| Robert McEwen | McEwen Mining | 73 | |
| Michael Balmuth | Ross Stores | 72 | |
| German Velasco | GMxico Transportes SAB | 66 | |
| Simon Zaga | FibraHotel | N/A | |
| Norman Ferber | Ross Stores | 74 | |
| Oscar Rocha | GMxico Transportes SAB | 85 | |
| Carlos Elizondo | Grupo Hotelero Santa | 54 | |
Management Performance
| Return On Equity | 0.24 | |||
| Return On Asset | 0.0881 |
Johnson Johnson Leadership Team
Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| A Washington, Independent Director | ||
| Dirk Brinckman, Chief Officer | ||
| Jennifer Doudna, Independent Director | ||
| Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee | ||
| Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer | ||
| Marillyn Hewson, Independent Director | ||
| Michael Ullmann, VP, General Counsel and Member of Executive Committee | ||
| Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals | ||
| Joseph CPA, Ex CFO | ||
| Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals | ||
| Mary Beckerle, Independent Director | ||
| Robert Decker, Controller Officer | ||
| Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices | ||
| Ronald Williams, Independent Director | ||
| Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| James Swanson, Ex Officer | ||
| D Davis, Independent Director | ||
| Hubert Joly, Independent Director | ||
| Anne Mulcahy, Lead Independent Director | ||
| Joseph Wolk, Chief Financial Officer, Executive Vice President | ||
| Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer | ||
| Jessica Moore, VP Relations | ||
| Ian Davis, Independent Director | ||
| Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee | ||
| Mark McClellan, Independent Director | ||
| Charles Prince, Independent Director | ||
| Elizabeth Forminard, Exec Counsel | ||
| Peter Fasolo, Chief Human Resource Officer, Executive Vice President | ||
| Mark Weinberger, Independent Director |
Johnson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.24 | |||
| Return On Asset | 0.0881 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 9.15 T | |||
| Shares Outstanding | 2.61 B | |||
| Shares Owned By Insiders | 0.09 % | |||
| Shares Owned By Institutions | 70.93 % | |||
| Price To Earning | 28.71 X | |||
| Price To Book | 6.26 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Johnson Stock Analysis
When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.